Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 5 examiners • 0 of 6 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Macrogenics Inc. is currently managing 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners and 3 distinct art units. This distribution indicates that while there is some overlap in the examiners, the prosecution is spread across multiple administrative units. The presence of 5 distinct examiners for 6 pending office actions suggests that most matters are receiving independent reviews, which can lead to a variety of outcomes within the portfolio. This variety requires practitioners to tailor their arguments to the specific preferences of multiple officials to ensure a cohesive strategy across the Biotechnology & Pharmaceuticals sector.
The busiest examiner for this portfolio is MOSELEY II, NELSON B, who is currently responsible for 2 pending office actions. This examiner holds more active matters than any other individual in the data, making their specific tendencies particularly important for the overall success of the portfolio. The involvement of 3 distinct art units indicates that the biotechnology applications cover several specialized technical areas. Practitioners must manage these 6 pending office actions by balancing the specific requirements of the 3 distinct art units and the individual preferences of the 5 distinct examiners involved. This complex distribution necessitates a versatile approach to the company's patent filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 2 | 68.0% | +41.5% |
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
| YU, MISOOK | 1 | 39.0% | +18.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18577945 | PHARMACEUTICAL COMPOSITIONS OF A B7-H3 ANTIBODY AND USE OF THE SAME | NATARAJAN, MEERA | — |
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18164952 | Covalent Diabodies and Uses Thereof | DUFFY, BRADLEY | 23d |
| 18577945 | PHARMACEUTICAL COMPOSITIONS OF A B7-H3 ANTIBODY AND USE OF THE SAME | NATARAJAN, MEERA | — |
| 18499658 | METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4 | MOSELEY II, NELSON B | — |
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | — |
| 18321354 | Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease | MOSELEY II, NELSON B | — |
| 18006294 | METHODS FOR THE USE OF A PD-1 X CTLA-4 BISPECIFIC MOLECULE | YU, MISOOK | — |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1643 | 2 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18577945 | PHARMACEUTICAL COMPOSITIONS OF A B7-H3 ANTIBODY AND USE OF THE SAME | NATARAJAN, MEERA | — | §102§112 | Non-Final OA | — | Pending | Jan 09, 2024 |
| 18499658 | METHODS OF USING BISPECIFIC MOLECULES HAVING IMMUNOREACTIVITY WITH PD-1 AND CTLA-4 | MOSELEY II, NELSON B | 1642 | §112DP | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18484921 | MULTl-CHAIN POLYPEPTIDE-CONTAINING TRI-SPECIFIC BINDING MOLECULES THAT SPECIFICALLY BIND TO MULTIPLE CANCER ANTIGENS | BRISTOL, LYNN ANNE | 1643 | §103§112Other | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18321354 | Variant CD3-Binding Domains and Their Use in Combination Therapies for the Treatment of Disease | MOSELEY II, NELSON B | 1642 | DP | Non-Final OA | — | Pending | May 22, 2023 |
| 18164952 | Covalent Diabodies and Uses Thereof | DUFFY, BRADLEY | 1643 | §103 | Final Rejection | 23d | Pending | Feb 06, 2023 |
| 18006294 | METHODS FOR THE USE OF A PD-1 X CTLA-4 BISPECIFIC MOLECULE | YU, MISOOK | 1641 | §102§103§112DPOther | Non-Final OA | — | Pending | Jan 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial